Literature DB >> 19092373

C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience.

Giampiero Giovacchini1, Federico Fallanca, Claudio Landoni, Luigi Gianolli, Piero Picozzi, Luca Attuati, Mariarosa Terreni, Maria Picchio, Cristina Messa, Ferruccio Fazio.   

Abstract

PURPOSE: Positron emission tomography/computed tomography (PET/CT) with C-11 choline has been used for staging, restaging, and follow-up of various tumors, whereas its role for imaging meningiomas has only been preliminarily explored. The aim of this study was to compare C-11 choline and F-18 fluorodeoxyglucose (F-18 FDG) uptake in meningiomas and relate these findings to the histopathological analysis.
METHODS: Two sequential three-dimensional PET/CT scans with 370 MBq (10 mCi) of C-11 choline and 370 MBq (10 mCi) of F-18 FDG were performed 2 hours apart in 7 patients with histologically confirmed meningiomas. Five patients had WHO grade I and 2 had WHO grade II meningioma. For each scan, two-dimensional regions of interest were drawn on tumor boundaries and on the contralateral side on CT images and copied to the corresponding PET images. SUVmax and tumor-to-background ratio were calculated.
RESULTS: Relative to the contralateral side, C-11 choline uptake was increased in all meningiomas, whereas F-18 FDG uptake was decreased in 6 patients and increased in 1 of the 2 patients with grade II meningiomas. In the whole group, SUVmax of C-11 choline and F-18 FDG were 3.6 +/- 1.3 and 5.7 +/- 1.3, respectively. The tumor-to-background ratio for C-11 choline was much higher than that for F-18 FDG (5.3 +/- 0.8 vs. 0.9 +/- 0.2, respectively) (P < 0.001). The uptake of C-11 choline was higher in patients with grade II than in grade I meningiomas.
CONCLUSIONS: These preliminary results suggest that C-11 choline may better image meningiomas in comparison with F-18 FDG. Clinical applications of C-11 choline PET/CT for grading and follow-up of meningiomas need to be assessed in further studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19092373     DOI: 10.1097/RLU.0b013e31818f4369

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  11 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography.

Authors:  Hideyuki Arita; Manabu Kinoshita; Yoshiko Okita; Ryuichi Hirayama; Tadashi Watabe; Kayako Ishohashi; Noriyuki Kijima; Naoki Kagawa; Yasunori Fujimoto; Haruhiko Kishima; Eku Shimosegawa; Jun Hatazawa; Naoya Hashimoto; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2011-11-17       Impact factor: 4.130

Review 3.  Current molecular imaging of spinal tumors in clinical practice.

Authors:  Nora Sandu; Gabriele Pöpperl; Marie-Elisabeth Toubert; Toma Spiriev; Belachew Arasho; Mikael Orabi; Bernhard Schaller
Journal:  Mol Med       Date:  2011-01-03       Impact factor: 6.354

Review 4.  PET imaging in patients with meningioma-report of the RANO/PET Group.

Authors:  Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

Review 5.  Intracranial meningiomas of atypical (WHO grade II) histology.

Authors:  Leland Rogers; Mark Gilbert; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2010-08-26       Impact factor: 4.130

6.  SPECT and PET imaging of meningiomas.

Authors:  Varvara Valotassiou; Anastasia Leondi; George Angelidis; Dimitrios Psimadas; Panagiotis Georgoulias
Journal:  ScientificWorldJournal       Date:  2012-05-01

Review 7.  The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.

Authors:  Ilanah J Pruis; Guus A M S van Dongen; Sophie E M Veldhuijzen van Zanten
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

8.  Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer.

Authors:  Marina Hodolic; Virginie Huchet; Sona Balogova; Laure Michaud; Khaldoun Kerrou; Valérie Nataf; Marino Cimitan; Jure Fettich; Jean-Noël Talbot
Journal:  Radiol Oncol       Date:  2014-07-10       Impact factor: 2.991

Review 9.  Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

Authors:  Riccardo Laudicella; Domenico Albano; Salvatore Annunziata; Diletta Calabrò; Giovanni Argiroffi; Elisabetta Abenavoli; Flavia Linguanti; Domenico Albano; Antonio Vento; Antonio Bruno; Pierpaolo Alongi; Matteo Bauckneht
Journal:  Cancers (Basel)       Date:  2019-09-22       Impact factor: 6.639

10.  Applications of PET in Diagnosis and Prognosis of Leukemia.

Authors:  Zixuan Zhao; Yanwen Hu; Jihui Li; Yeye Zhou; Bin Zhang; Shengming Deng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.